Immunogenicity

Home 5 Immunogenicity

Early Immunogenicity Risk Assessment Across Drug Programs

At PI Health Sciences, our platform delivers comprehensive in vitro immunogenicity risk assessment services designed to advance synthetic peptide therapeutics and generic peptide products from early development through ANDA submissions. We enable rational evaluation of innate and adaptive immune responses through a unified framework that combines in silico prediction, human cell-based assays, and regulatory-aligned study design.

Our services address the unique immunogenicity challenges of synthetic peptides and peptide-related impurities, including T cell epitope content, innate immune response modulating impurities (IIRMIs), HLA presentation, and formulation-driven activation. By integrating in silico screening, PBMC-based functional assays, and comparative RLD testing, we ensure immunogenicity risk and developability are evaluated together, supporting confident regulatory decision-making.

Supporting peptide ANDAs and peptide therapeutics across multiple therapeutic areas, our teams operate within a science-driven, FDA- and EMA-aligned framework. Programs are designed with comparative immunogenicity assessment, impurity control strategies, and downstream regulatory expectations in mind, enabling confident progression toward IND-enabling studies and ANDA submissions.

In Silico versus In Vitro Immunogenicity Assessment

This integration improves efficiency, reduces experimental burden, and strengthens the overall weight of evidence for ANDA and peptide development programs.

Aspect	In Silico Immunogenicity Assessment	In Vitro Immunogenicity Assessment
Primary objective	Early prediction of peptide and impurity T cell epitope risk	Experimental confirmation of innate and adaptive immune activation
Typical inputs	Peptide sequence, HLA allele set, structural or population data	Final or clinical-like formulations tested on human PBMCs and subsets
Readouts	Predicted HLA binding, T cell epitope density and immunogenicity scores	Cytokines, chemokines, cell activation markers, T cell proliferation
Throughput and speed	High-throughput, fast and cost-effective for large peptide libraries	Moderate throughput; more resource- and time-intensive per candidate
Biological relevance	Model-based risk ranking; not a substitute for experimental data	Direct human cell response data, better reflecting clinical biology
Regulatory positioning	Supports candidate selection and justification of impurity scopes	Supports FDA expectations for non-clinical immunogenicity evaluation of peptide generics

Capabilities

In Silico Immunogenicity Risk Assessment

Our integrated computational platform combines T cell epitope prediction, HLA binding analysis, and structural bioinformatics to prioritize high-risk peptide sequences and impurities for focused in vitro testing.

PBMC-Based Innate Immunostimulation (IIRMI) Assays

We evaluate innate immune response modulating impurities using human PBMC assays aligned with FDA recommendations for generic peptide products, including side-by-side comparison with reference listed drugs.

Adaptive T Cell Immunogenicity Assays

Our T cell assays measure peptide-specific adaptive immune responses using HLA-diverse human donor panels, providing functional confirmation of in silico predictions and comparative immunogenicity risk assessment.

Impurity-Focused Immunogenicity Testing

We characterize the immunogenicity of individual peptide-related impurities, degradants, and aggregates to rank their risk relative to the API and inform specification setting for ANDA submissions.

Assay Validation and Regulatory-Ready Reporting

We ensure all in vitro immunogenicity assays are fit-for-purpose validated with documented precision, sensitivity, specificity, and acceptance criteria consistent with FDA and EMA expectations.

Integrated In Silico and In Vitro Workflow

Our tightly integrated computational-experimental workflow enables rapid, orthogonal immunogenicity risk assessment from sequence prediction through functional validation, aligned with FDA and EMA expectations for peptide generics.

Frequently asked questions

We’re here to help with any questions you have about our plans, supported features, and how our model works.

How does PI Health Sciences approach integrated in vitro immunogenicity assessment for synthetic peptides?

PI Health Sciences executes peptide immunogenicity programs as unified workflows where in silico prediction, PBMC-based functional assays, and analytical characterization inform each other continuously. Computational epitope mapping guides experimental prioritization, human cell response data refines risk hypotheses, and comparative RLD testing shapes regulatory justification, resulting in coherent, decision-ready datasets aligned with FDA and EMA expectations.

What differentiates PI Health Sciences in vitro immunogenicity services from conventional approaches?

Our services focus on mechanistic understanding of both innate (IIRMI) and adaptive (T cell) immune activation, comparative RLD assessment, and impurity-specific risk ranking from the outset. This integrated approach minimizes false conclusions driven by analytical characterization alone and prioritizes data packages with true regulatory value for ANDA submissions and peptide therapeutic development.

How are immunogenicity risk and impurity control strategies balanced during assessment?

Risk assessment decisions are guided by simultaneous evaluation of in silico epitope predictions, experimental PBMC and T cell responses, impurity abundance, and RLD comparability. This prevents over-reliance on computational predictions at the expense of biological confirmation and ensures impurity specifications are justified by functional immunogenicity data, not analytical limits alone.

Can PI Health Sciences support peptide products beyond classical small synthetic peptides?

In addition to small synthetic peptides and their generics, we support modified peptides (PEGylated, fatty-acid conjugated), fusion constructs, and peptide-related biologics, applying the same integration principles of in silico screening, functional in vitro validation, and regulatory-aligned risk assessment.

Which synthetic peptides require in vitro immunogenicity assessment?

In vitro immunogenicity and impurity-focused assays are particularly recommended for synthetic generics referencing glucagon, liraglutide, nesiritide, teriparatide, and teduglutide, as outlined in the FDA synthetic peptide guidance. Services also support other peptide APIs with known immunogenicity (such as salmon calcitonin, exenatide, and related GLP-1/GLP-2 analogs), as well as any synthetic peptide where sequence, modification pattern, or impurity profile may increase immunogenicity risk.

How do HLA binding assays support immunogenicity risk assessment for peptide products?

HLA binding assays identify whether your peptide or its impurities can bind to common human HLA class II molecules, which is the critical first step for T cell recognition and adaptive immune responses. By testing binding across a panel of frequent HLA-DR alleles, we estimate the proportion of the patient population that might present your peptide to their immune system. These experimental binding data validate in silico epitope predictions and help prioritize which peptides and impurities pose the highest immunogenicity risk. When combined with functional T cell assays, HLA binding results provide a complete picture-from antigen presentation potential through actual T cell activation-strengthening the regulatory justification for peptide selection, impurity control, and generic-reference comparability claims.

Contact Us

Connect with PI Health Sciences to explore how our integrated in silico and in vitro immunogenicity assessment capabilities can support your development programs, from early epitope risk prediction and impurity profiling to PBMC-based functional validation and regulatory-aligned immunogenicity risk mitigation strategies.